Potential of pharmacokinetic profiling for detecting herbal interactions with drugs

被引:32
作者
Butterweck, Veronika [1 ]
Derendorf, Hartmut [1 ]
机构
[1] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA
关键词
D O I
10.2165/00003088-200847060-00003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The issue of herb-drug interactions has generated significant concern within the pharmaceutical industry and among regulatory authorities in recent years. Therefore, accurate models of predicting metabolic herb-drug interactions would be useful tools in efforts to avoid toxic adverse events. However, the majority of pharmacokinetic interactions listed for herbal medicinal products are based on theoretical predictions of the in vitro pharmacological effects of known constituents, which do not necessarily have to be the active ingredients. The prediction of herb-drug interactions is further complicated by the fact that pharmacokinetic data on active or (at least) known ingredients are often not available. The present article discusses the potential of pharmacokinetic profiling for detecting herb-drug interactions, using the most frequently cited interactions in the literature as examples. In particular, common mechanisms of herb-drug interactions are summarized, and the available experimental methods for detecting such interactions, as well as the limitations of these models, are critically evaluated. In addition, we discuss the question of whether the existing methods of detecting herb-drug interactions correlate with the clinical relevance. Effective screening tools that accurately predict metabolic herb-drug interactions would offer a tremendous advantage because it is not possible to study all potential herb-drug interactions in clinical trials.
引用
收藏
页码:383 / 397
页数:15
相关论文
共 123 条
[41]  
GRIMM SW, 1995, DRUG METAB DISPOS, V23, P577
[42]  
Guengerich F P, 1997, Adv Pharmacol, V43, P7, DOI 10.1016/S1054-3589(08)60200-8
[43]   Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: Comparison of a milk thistle and black cohosh product to rifampin and clarithromycin [J].
Gurley, B ;
Hubbard, MA ;
Williams, DK ;
Thaden, J ;
Tong, YD ;
Gentry, WB ;
Breen, P ;
Carrier, DJ ;
Cheboyina, S .
JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (02) :201-213
[44]   Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans [J].
Gurley, BJ ;
Barone, GW ;
Williams, DK ;
Carrier, J ;
Breen, P ;
Yates, CR ;
Song, PF ;
Hubbard, MA ;
Tong, YD ;
Cheboyina, S .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (01) :69-74
[45]   In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes:: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto [J].
Gurley, BJ ;
Gardner, SF ;
Hubbard, MA ;
Williams, DK ;
Gentry, WB ;
Carrier, J ;
Khan, IA ;
Edwards, DJ ;
Shah, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (05) :428-440
[46]   Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans [J].
Gurley, BJ ;
Gardner, SF ;
Hubbard, MA ;
Williams, DK ;
Gentry, WB ;
Cui, Y ;
Ang, CYW .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (03) :276-287
[47]  
HALPERT JR, 1995, ANNU REV PHARMACOL, V35, P29, DOI 10.1146/annurev.pharmtox.35.1.29
[48]   St. John's wort: A systematic review of adverse effects and drug interactions for the consultation psychiatrist [J].
Hammerness, P ;
Basch, E ;
Ulbricht, C ;
Barrette, EP ;
Foppa, I ;
Basch, S ;
Bent, S ;
Boon, H ;
Ernst, E .
PSYCHOSOMATICS, 2003, 44 (04) :271-282
[49]   Dietary effects on drug metabolism and transport [J].
Harris, RZ ;
Jang, GR ;
Tsunoda, S .
CLINICAL PHARMACOKINETICS, 2003, 42 (13) :1071-1088
[50]   St John's wort (Hypericum perforatum):: drug interactions and clinical outcomes [J].
Henderson, L ;
Yue, QY ;
Bergquist, C ;
Gerden, B ;
Arlett, P .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (04) :349-356